Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.02
RAD's Cash to Debt is ranked lower than
98% of the 371 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.62 vs. RAD: 0.02 )
Ranked among companies with meaningful Cash to Debt only.
RAD' s Cash to Debt Range Over the Past 10 Years
Min: 0  Med: 0.03 Max: 0.1
Current: 0.02
0
0.1
Equity to Asset 0.05
RAD's Equity to Asset is ranked lower than
97% of the 370 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.43 vs. RAD: 0.05 )
Ranked among companies with meaningful Equity to Asset only.
RAD' s Equity to Asset Range Over the Past 10 Years
Min: -0.35  Med: 0.00 Max: 0.39
Current: 0.05
-0.35
0.39
Interest Coverage 1.67
RAD's Interest Coverage is ranked lower than
91% of the 304 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 13.76 vs. RAD: 1.67 )
Ranked among companies with meaningful Interest Coverage only.
RAD' s Interest Coverage Range Over the Past 10 Years
Min: 0.02  Med: 1.09 Max: 2.11
Current: 1.67
0.02
2.11
F-Score: 4
Z-Score: 2.93
M-Score: -2.05
WACC vs ROIC
18.37%
6.54%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 2.44
RAD's Operating margin (%) is ranked lower than
54% of the 371 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.94 vs. RAD: 2.44 )
Ranked among companies with meaningful Operating margin (%) only.
RAD' s Operating margin (%) Range Over the Past 10 Years
Min: -7.81  Med: 1.29 Max: 3.16
Current: 2.44
-7.81
3.16
Net-margin (%) 0.54
RAD's Net-margin (%) is ranked lower than
70% of the 372 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.75 vs. RAD: 0.54 )
Ranked among companies with meaningful Net-margin (%) only.
RAD' s Net-margin (%) Range Over the Past 10 Years
Min: -11.09  Med: -0.63 Max: 7.95
Current: 0.54
-11.09
7.95
ROE (%) 48.05
RAD's ROE (%) is ranked higher than
98% of the 364 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 8.83 vs. RAD: 48.05 )
Ranked among companies with meaningful ROE (%) only.
RAD' s ROE (%) Range Over the Past 10 Years
Min: -1148.43  Med: -33.10 Max: 51.83
Current: 48.05
-1148.43
51.83
ROA (%) 1.52
RAD's ROA (%) is ranked lower than
67% of the 373 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.19 vs. RAD: 1.52 )
Ranked among companies with meaningful ROA (%) only.
RAD' s ROA (%) Range Over the Past 10 Years
Min: -29.43  Med: -2.28 Max: 26.83
Current: 1.52
-29.43
26.83
ROC (Joel Greenblatt) (%) 19.48
RAD's ROC (Joel Greenblatt) (%) is ranked higher than
62% of the 371 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 14.63 vs. RAD: 19.48 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
RAD' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -44.02  Med: 7.10 Max: 22.13
Current: 19.48
-44.02
22.13
Revenue Growth (3Y)(%) 1.80
RAD's Revenue Growth (3Y)(%) is ranked lower than
66% of the 317 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.10 vs. RAD: 1.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
RAD' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -16  Med: -3.00 Max: 11
Current: 1.8
-16
11
EBITDA Growth (3Y)(%) 4.70
RAD's EBITDA Growth (3Y)(%) is ranked lower than
52% of the 286 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.20 vs. RAD: 4.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
RAD' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -15.6  Med: -1.90 Max: 24.2
Current: 4.7
-15.6
24.2
EPS Growth (3Y)(%) 10.50
RAD's EPS Growth (3Y)(%) is ranked higher than
62% of the 243 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.10 vs. RAD: 10.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
RAD' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -59.9  Med: 1.30 Max: 479.9
Current: 10.5
-59.9
479.9
» RAD's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-06-18)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2015

RAD Guru Trades in Q2 2015

First Eagle Investment 1,596,105 sh (New)
John Burbank 11,495,343 sh (+177.57%)
Paul Tudor Jones 290,532 sh (+24.56%)
Ken Fisher 11,500 sh (+11.11%)
Louis Moore Bacon 500,000 sh (unchged)
Louis Moore Bacon Sold Out
Joel Greenblatt 3,253,782 sh (-5.27%)
Larry Robbins 12,548,751 sh (-10.32%)
Jim Simons 368,900 sh (-93.24%)
Ray Dalio 70,374 sh (-95.86%)
» More
Q3 2015

RAD Guru Trades in Q3 2015

First Eagle Investment 5,023,390 sh (+214.73%)
Louis Moore Bacon 550,000 sh (unchged)
Ken Fisher Sold Out
John Burbank Sold Out
Ray Dalio Sold Out
Jim Simons Sold Out
Paul Tudor Jones Sold Out
Larry Robbins 12,357,751 sh (-1.52%)
Joel Greenblatt 2,491,729 sh (-23.42%)
» More
Q4 2015

RAD Guru Trades in Q4 2015

Jeremy Grantham 5,540,600 sh (New)
Mario Gabelli 717,400 sh (New)
Eric Mindich 8,203,124 sh (New)
Ken Fisher 10,809 sh (New)
George Soros 808,700 sh (New)
Pioneer Investments 922,139 sh (New)
First Eagle Investment 5,627,170 sh (+12.02%)
Paul Tudor Jones 100,100 sh (unchged)
Larry Robbins Sold Out
Joel Greenblatt 167,539 sh (-93.28%)
» More
Q1 2016

RAD Guru Trades in Q1 2016

Ken Fisher Sold Out
First Eagle Investment Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with RAD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Rite Aid Corp

SymbolPriceYieldDescription
RADCO0.000.00Conv Pfd Shs Series -I-

Top Ranked Articles about Rite Aid Corp

How the Walgreens-Rite Aid Deal Stacks Up Against Paulson's Merger Arbitrage Checklist Deal may be overvalued according to M&A guru John Paulson's framework for evaluating mergers
Walgreens Boots Alliance (NASDAQ:WBA) announced on Oct. 27 it would acquire Rite Aid (NYSE:RAD) in a deal worth more than $17 billion, combining the largest and third-largest drugstore chains in the country in terms of number of stores. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 50.00
RAD's P/E(ttm) is ranked lower than
87% of the 305 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.69 vs. RAD: 50.00 )
Ranked among companies with meaningful P/E(ttm) only.
RAD' s P/E(ttm) Range Over the Past 10 Years
Min: 3.17  Med: 15.61 Max: 6590
Current: 50
3.17
6590
Forward P/E 26.46
RAD's Forward P/E is ranked lower than
93% of the 72 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 17.54 vs. RAD: 26.46 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 50.00
RAD's PE(NRI) is ranked lower than
87% of the 301 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.69 vs. RAD: 50.00 )
Ranked among companies with meaningful PE(NRI) only.
RAD' s PE(NRI) Range Over the Past 10 Years
Min: 3.17  Med: 15.25 Max: 219
Current: 50
3.17
219
Price/Owner Earnings (ttm) 15.90
RAD's Price/Owner Earnings (ttm) is ranked higher than
62% of the 186 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 21.57 vs. RAD: 15.90 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
RAD' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 2.91  Med: 11.20 Max: 547.5
Current: 15.9
2.91
547.5
P/B 14.39
RAD's P/B is ranked lower than
99% of the 363 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.81 vs. RAD: 14.39 )
Ranked among companies with meaningful P/B only.
RAD' s P/B Range Over the Past 10 Years
Min: 0.29  Med: 2.13 Max: 151.55
Current: 14.39
0.29
151.55
P/S 0.27
RAD's P/S is ranked higher than
67% of the 366 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.47 vs. RAD: 0.27 )
Ranked among companies with meaningful P/S only.
RAD' s P/S Range Over the Past 10 Years
Min: 0.01  Med: 0.10 Max: 0.34
Current: 0.27
0.01
0.34
PFCF 24.93
RAD's PFCF is ranked lower than
63% of the 147 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.08 vs. RAD: 24.93 )
Ranked among companies with meaningful PFCF only.
RAD' s PFCF Range Over the Past 10 Years
Min: 1.85  Med: 19.03 Max: 605.33
Current: 24.93
1.85
605.33
POCF 8.30
RAD's POCF is ranked higher than
61% of the 187 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 10.23 vs. RAD: 8.30 )
Ranked among companies with meaningful POCF only.
RAD' s POCF Range Over the Past 10 Years
Min: 0.52  Med: 6.62 Max: 84.58
Current: 8.3
0.52
84.58
EV-to-EBIT 20.93
RAD's EV-to-EBIT is ranked lower than
70% of the 304 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 15.79 vs. RAD: 20.93 )
Ranked among companies with meaningful EV-to-EBIT only.
RAD' s EV-to-EBIT Range Over the Past 10 Years
Min: -2324  Med: 20.20 Max: 3729.2
Current: 20.93
-2324
3729.2
EV-to-EBITDA 12.29
RAD's EV-to-EBITDA is ranked lower than
55% of the 314 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 11.30 vs. RAD: 12.29 )
Ranked among companies with meaningful EV-to-EBITDA only.
RAD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -6.2  Med: 11.80 Max: 17.3
Current: 12.29
-6.2
17.3
PEG 2.92
RAD's PEG is ranked lower than
61% of the 153 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.21 vs. RAD: 2.92 )
Ranked among companies with meaningful PEG only.
RAD' s PEG Range Over the Past 10 Years
Min: 0.16  Med: 0.22 Max: 4.6
Current: 2.92
0.16
4.6
Current Ratio 1.52
RAD's Current Ratio is ranked higher than
64% of the 355 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.20 vs. RAD: 1.52 )
Ranked among companies with meaningful Current Ratio only.
RAD' s Current Ratio Range Over the Past 10 Years
Min: 0.81  Med: 1.81 Max: 2.36
Current: 1.52
0.81
2.36
Quick Ratio 0.62
RAD's Quick Ratio is ranked lower than
61% of the 355 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.74 vs. RAD: 0.62 )
Ranked among companies with meaningful Quick Ratio only.
RAD' s Quick Ratio Range Over the Past 10 Years
Min: 0.18  Med: 0.50 Max: 0.78
Current: 0.62
0.18
0.78
Days Inventory 45.17
RAD's Days Inventory is ranked lower than
57% of the 359 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 40.31 vs. RAD: 45.17 )
Ranked among companies with meaningful Days Inventory only.
RAD' s Days Inventory Range Over the Past 10 Years
Min: 44.45  Med: 63.29 Max: 70.58
Current: 45.17
44.45
70.58
Days Sales Outstanding 19.01
RAD's Days Sales Outstanding is ranked lower than
57% of the 287 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 13.88 vs. RAD: 19.01 )
Ranked among companies with meaningful Days Sales Outstanding only.
RAD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 7.31  Med: 13.54 Max: 19.01
Current: 19.01
7.31
19.01
Days Payable 24.58
RAD's Days Payable is ranked lower than
82% of the 299 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 46.29 vs. RAD: 24.58 )
Ranked among companies with meaningful Days Payable only.
RAD' s Days Payable Range Over the Past 10 Years
Min: 21.83  Med: 25.85 Max: 29.42
Current: 24.58
21.83
29.42

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.79
RAD's Price/Projected FCF is ranked lower than
76% of the 210 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.48 vs. RAD: 2.79 )
Ranked among companies with meaningful Price/Projected FCF only.
RAD' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.71  Med: 2.77 Max: 8.67
Current: 2.79
1.71
8.67
Price/Median PS Value 2.71
RAD's Price/Median PS Value is ranked lower than
97% of the 322 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.10 vs. RAD: 2.71 )
Ranked among companies with meaningful Price/Median PS Value only.
RAD' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.09  Med: 1.20 Max: 8.1
Current: 2.71
0.09
8.1
Price/Peter Lynch Fair Value 2.63
RAD's Price/Peter Lynch Fair Value is ranked lower than
76% of the 103 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.79 vs. RAD: 2.63 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
RAD' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.21  Med: 2.52 Max: 3.78
Current: 2.63
0.21
3.78
Earnings Yield (Greenblatt) (%) 4.82
RAD's Earnings Yield (Greenblatt) (%) is ranked lower than
57% of the 368 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.50 vs. RAD: 4.82 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
RAD' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.3  Med: 4.80 Max: 8.2
Current: 4.82
0.3
8.2
Forward Rate of Return (Yacktman) (%) 21.52
RAD's Forward Rate of Return (Yacktman) (%) is ranked higher than
84% of the 225 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 7.24 vs. RAD: 21.52 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
RAD' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -31.7  Med: -0.15 Max: 52.3
Current: 21.52
-31.7
52.3

More Statistics

Revenue(Mil) $30737
EPS $ 0.16
Beta2.06
Short Percentage of Float4.02%
52-Week Range $5.88 - 9.47
Shares Outstanding(Mil)1048.41

Analyst Estimate

Feb17 Feb18
Revenue(Mil) 33,532 34,601
EPS($) 0.30 0.47
EPS without NRI($) 0.30 0.47

Business Description

Industry: Retail - Defensive » Pharmaceutical Retailers
Compare:NAS:WBA, BSP:RADL3, TSE:3391, SHSE:600998, TSE:9989 » details
Traded in other countries:RTA.Germany,
Rite Aid Corp a Delaware corporation was incorporated in 1968. It operates retail drugstore chain in the United States. It operates its drugstores in 31 states across the country and in the District of Columbia. As of February 28, 2015, the Company operated 4,570 stores in 31 states across the country and in the District of Columbia. The Company sells prescription drugs and an assortment of other merchandise, which it calls 'front end' products. Front end products include over-the-counter medications, health and beauty aids, personal care items, cosmetics, household items, food and beverages, greeting cards, seasonal merchandise and numerous other convenience products. The Company attempts to distinguish its stores from other national chain drugstores, in part, through its wellness + loyalty program, private brands and its strategic alliance with GNC, a retailer of vitamin and mineral supplements. The retail drugstore industry is competitive. It competes with retail drugstore chains, independently owned drugstores, supermarkets, mass merchandisers, discount stores, wellness offerings, dollar stores and mail order pharmacies. The Company's business is subject to federal, state, and local government laws, regulations and administrative practices.
» More Articles for RAD

Headlines

Articles On GuruFocus.com
Undervalued Stocks With Low PE Mar 24 2016 
Is CVS Pharmacy Undervalued? Feb 22 2016 
Steven Romick Reduces 7 Stakes in 4th Quarter Jan 28 2016 
John Burbank Jumps in Alphabet, Dollar Tree and Sells Rite Aid, NRG Nov 25 2015 
Leon Cooperman Buys Several Health Care Companies, Brief Position in Valeant Nov 17 2015 
How the Walgreens-Rite Aid Deal Stacks Up Against Paulson's Merger Arbitrage Checklist Nov 05 2015 
How Rite Aid Deal Will Change Walgreens Oct 30 2015 
Rite Aid Corporation Posts Impressive Results Jun 23 2015 
Walgreens Boots Alliance, Inc. Dividend Stock Analysis Jun 09 2015 
Larry Robbins' New Buys During Q1 2015 May 29 2015 

More From Other Websites
Moody's Upgrades Two and Affirms Two Classes of LBCMT 1999-C1 May 05 2016
U.S. retailers' April same-store sales May 05 2016
Rite Aid Foundation’s KidCents Program Donates $100,000 to Hurley Children’s Hospital May 05 2016
ETF’s with exposure to Rite-Aid Corp. : May 4, 2016 May 04 2016
Rite-Aid Corp. breached its 50 day moving average in a Bearish Manner : RAD-US : May 4, 2016 May 04 2016
CVS Earnings Top Views But Growth Slowest In Over 2 Years May 03 2016
RITE AID CORP Financials Apr 29 2016
RITE AID CORP Files SEC form 10-K, Annual Report Apr 25 2016
Cramer likes UnitedHealth After Strong Earnings Apr 19 2016
Rite-Aid Corp. – Value Analysis (NYSE:RAD) : April 19, 2016 Apr 19 2016
Rite Aid Announces Winners of 12th Annual Favorite Pharmacy Team Member Contest Apr 19 2016
Rite Aid Announces Winners of 12th Annual Favorite Pharmacy Team Member Contest Apr 19 2016
Jim Cramer: Waiting for Rite Aid Is a Drag on Walgreens' Shares Apr 18 2016
Jim Cramer: Rite Aid Is a Play on Walgreens Deal Apr 18 2016
Rite-Aid Corp. breached its 50 day moving average in a Bearish Manner : RAD-US : April 18, 2016 Apr 18 2016
How to Forecast Rite Aid's Revenue (RAD) Apr 18 2016
ETF’s with exposure to Rite-Aid Corp. : April 17, 2016 Apr 17 2016
Rite-Aid Corp. :RAD-US: Earnings Analysis: Q4, 2016 By the Numbers Apr 14 2016
Rite-Aid Corp. :RAD-US: Earnings Analysis: 2016 By the Numbers Apr 14 2016
Rite Aid (RAD) Comps Concerns Prevail: Should You Dump? Apr 12 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK